Novartis AG ADR(NVS) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Nov 13 at 5:24 PM ET (Korea 11/14 07:24)AI-drawn chart patterns are for reference only.
Full metrics table
| Index | - | P/E | 30.65 | EPS (ttm) | 5.24 | Insider Own | 0.01% | Shs Outstand | 1.89B | Perf Week | -1.26% |
| Market Cap | 293.80B | Forward P/E | 16.23 | EPS next Y | 10.99% | Insider Trans | - | Shs Float | 1.83B | Perf Month | 6.73% |
| Enterprise Value | 333.47B | PEG | 2.51 | EPS next Q | 2.25 | Inst Own | 7.41% | Short Float | 0.25% | Perf Quarter | 5.61% |
| Income | 10.04B | P/S | 5.31 | EPS this Y | -0.81% | Inst Trans | 7.78% | Short Ratio | 2.13 | Perf Half Y | 8.39% |
| Sales | 55.35B | P/B | 8.14 | EPS next 5Y | 6.46% | ROA | 8.95% | Short Interest | 4.52M | Perf YTD | 16.41% |
| Book/sh | 19.71 | P/C | 32.74 | EPS past 3/5Y | 31.4% 15.24% | ROE | 24.62% | 52W High | -5.84% ($170.46) | Perf Year | 21.67% |
| Cash/sh | 4.9 | P/FCF | 18.78 | Sales past 3/5Y | 9.03% 2.29% | ROIC | 13.28% | 52W Low | 30.23% ($123.24) | Perf 3Y | 70.58% |
| Dividend Est. | $4.39 (2.74%) | EV/EBITDA | 15.08 | EPS Y/Y TTM | -28.72% | Gross Margin | 74.3% | Volatility(W/M) | 1.08% 1.64% | Perf 5Y | 105.62% |
| Dividend TTM | 4.74 | EV/Sales | 6.02 | Sales Y/Y TTM | 1.64% | Oper. Margin | 30.47% | ATR (14) | 3.05 | Perf 10Y | 157.67% |
| Dividend Ex-Date | 2026/3/11 | Quick Ratio | 0.7 | EPS Q/Q | -68.95% | Profit Margin | 18.14% | RSI (14) | 58.46 | Recom | 2 |
| Dividend Gr. 3/5Y | 10.71% 8.17% | Current Ratio | 0.88 | Sales Q/Q | 4.03% | SMA20 | 1.2% ($158.6) | Beta | 0.41 | Target Price | $159.5 |
| Payout | 42.5% | Debt/Eq | 1.3 | Earnings | 2026/10/27 | SMA50 | 7.62% ($149.14) | Rel Volume | 0.67 | Prev Close | $160.25 |
| Employees | 75267 | LT Debt/Eq | 1.03 | EPS/Sales Surpr. | 8.32% -0.07% | SMA200 | 5.2% ($152.57) | Avg Volume(3M) | 2.12M | Price | $160.5 |
| IPO | 1996/11/7 | Option/Short | Yes/Yes | Trades | 17454 | Volume | 1,417,488 | Change | 0.16% |
💊 A global large pharmaceutical company developing innovative medicines in oncology, cardiovascular, immunology, and neuroscience. It was established in 1996 through the merger of Ciba-Geigy and Sandoz, and is headquartered in Switzerland, with its U.S. stock market listing in the form of an American Depositary Receipt (ADR).
Over the past 1 year, on the higher side
6% below its 1-year high.
Traded less than usual. That is 67% of its average volume.
NVS makes money exceptionally well
Of every $100 in sales, $30.47 is kept as operating profit.
Tap to view numbers
Growth is moderate
Earnings are expected to grow by -0.8% this year.
Tap to view numbers
The price is about the industry average
For a company earning $100 a year, you would pay $3,065. Peers typically go for $2,701.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have paid off
Bought 5 years ago, your return today would be +105.6%. The S&P 500 did +61% over the same period.
Tap to view numbers
Dividends are paid consistently
Pays 2.74% annually in dividends.
Tap to view numbers
Institutions barely hold it
Institutions hold 7.4%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
It ranks #5 of 21 in the industry
Based on market cap of $294B.
MRK#4 Merck & Co Inc $364B PER 150.9 
NVS#5 Novartis AG ADR $294B PER 30.6 
AZN#6 Astrazeneca plc $286B PER 26.1 
AMGN#7 AMGEN Inc $252B PER 27.0 
GILD#8 Gilead Sciences Inc $208B PER - 
FAQ
What kind of company is NVS?
NVS belongs to the Healthcare sector and operates in the Drug Manufacturers - General industry.
What is the market cap of NVS?
The market cap of NVS is approximately $293.8B, ranking 43 within its sector.
Does NVS pay dividends?
NVS has a dividend yield of approximately 2.74%, with an annual dividend of $4.39.
What is the P/E ratio of NVS?
NVS has a P/E ratio of approximately 30.6x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for NVS?
NVS has recorded a 52-week high of $170.46 and a low of $123.24.
